Accepted for/Published in: Interactive Journal of Medical Research
Date Submitted: Nov 1, 2022
Date Accepted: Jan 20, 2023
Non-Drug Intervention for Opportunistic Infection in Individuals with Haematological Malignancy: A Systematic Review
ABSTRACT
Background:
Haematological cancer disturbs the bone marrow, lymph nodes and bone marrow. Taking medications for treating opportunistic infection (OI) in these individuals may enhance the risk of medication interaction as well as adverse drug reactions.
Objective:
To measure the efficiency of non-pharmacological measures to prevent OI in individuals with haematological cancers.
Methods:
The relevant articles were searched in MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL) and EMBASE, up to September 2022. In this review, articles reported randomized controlled trials (RCTs) were included.
Results:
Findings included five RCTs that evaluated different interventions in preventing OI; (i) chlorhexidine rinse; (ii) chlorhexidine-nystatin rinse; (iii) nystatin rinse (iv) chlorhexidine silver-sulphadiazine coated central venous catheters (CVC); (v) well-fitted mask; (vi) amide fluoride-stannous fluoride and (vii) low bacterial diet. No clear differences were reported for all comparisons.
Conclusions:
Limited evidence was available to measure the effectiveness of non-drug intervention in haematological malignancies. The effectiveness of the interventions included in this review needs to be evaluated further in high-quality RCTs in a dedicated setting among patients with haematological malignancies. Clinical Trial: PROSPERO CRD42020169186
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.